5 Stocks Dragging In The Health Care Sector

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 78 points (-0.5%) at 14,583 as of Wednesday, April 3, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 720 issues advancing vs. 2,193 declining with 115 unchanged.

The Health Care sector currently sits down 1.0% versus the S&P 500, which is down 0.7%. On the negative front, top decliners within the sector include Tenet Healthcare ( THC), down 5.9%, Pharmacyclics Incorporated ( PCYC), down 5.5%, HCA Holdings ( HCA), down 4.7%, Sanofi ( SNY), down 0.8% and Baxter International ( BAX), down 0.7%.

TheStreet Ratings group would like to highlight 5 stocks pushing the sector lower today:

5. Biogen Idec ( BIIB) is one of the companies pushing the Health Care sector lower today. As of noon trading, Biogen Idec is down $2.88 (-1.4%) to $195.31 on heavy volume Thus far, 1.2 million shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $195.14-$199.05 after having opened the day at $198.38 as compared to the previous trading day's close of $198.19.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $45.6 billion and is part of the drugs industry. The company has a P/E ratio of 33.5, above the S&P 500 P/E ratio of 17.7. Shares are up 35.4% year to date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and growth in earnings per share. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Biogen Idec Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

4. As of noon trading, Celgene Corporation ( CELG) is down $2.28 (-1.9%) to $115.51 on average volume Thus far, 1.8 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3.8 million shares. The stock has ranged in price between $114.88-$118.30 after having opened the day at $117.87 as compared to the previous trading day's close of $117.79.

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies to treat cancer and immune-inflammatory related diseases in the United States, Europe, and other countries. Celgene Corporation has a market cap of $49.0 billion and is part of the drugs industry. The company has a P/E ratio of 35.5, above the S&P 500 P/E ratio of 17.7. Shares are up 50.1% year to date as of the close of trading on Tuesday. Currently there are 23 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

3. As of noon trading, Gilead ( GILD) is down $0.54 (-1.1%) to $47.66 on light volume Thus far, 3.5 million shares of Gilead exchanged hands as compared to its average daily volume of 9.8 million shares. The stock has ranged in price between $47.56-$48.37 after having opened the day at $48.25 as compared to the previous trading day's close of $48.20.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $73.1 billion and is part of the drugs industry. The company has a P/E ratio of 29.3, above the S&P 500 P/E ratio of 17.7. Shares are up 31.2% year to date as of the close of trading on Tuesday. Currently there are 19 analysts that rate Gilead a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, increase in net income, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Gilead Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

2. As of noon trading, Amgen ( AMGN) is down $1.88 (-1.8%) to $104.52 on average volume Thus far, 3.1 million shares of Amgen exchanged hands as compared to its average daily volume of 5.8 million shares. The stock has ranged in price between $104.43-$106.79 after having opened the day at $106.68 as compared to the previous trading day's close of $106.40.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $76.6 billion and is part of the drugs industry. The company has a P/E ratio of 18.5, above the S&P 500 P/E ratio of 17.7. Shares are up 23.4% year to date as of the close of trading on Tuesday. Currently there are 13 analysts that rate Amgen a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Amgen Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

1. As of noon trading, Pfizer ( PFE) is down $0.25 (-0.9%) to $28.98 on average volume Thus far, 19.8 million shares of Pfizer exchanged hands as compared to its average daily volume of 31.8 million shares. The stock has ranged in price between $28.88-$29.34 after having opened the day at $29.23 as compared to the previous trading day's close of $29.23.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $207.2 billion and is part of the drugs industry. The company has a P/E ratio of 22.9, above the S&P 500 P/E ratio of 17.7. Shares are up 16.6% year to date as of the close of trading on Tuesday. Currently there are 14 analysts that rate Pfizer a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Pfizer Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null